A detailed history of Hyman Charles D transactions in Pfizer Inc stock. As of the latest transaction made, Hyman Charles D holds 155,313 shares of PFE stock, worth $4.4 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
155,313
Previous 151,886 2.26%
Holding current value
$4.4 Million
Previous $4.37 Million 1.44%
% of portfolio
0.24%
Previous 0.26%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$25.89 - $29.73 $88,725 - $101,884
3,427 Added 2.26%
155,313 $4.31 Million
Q4 2023

Feb 06, 2024

SELL
$26.13 - $33.94 $28,533 - $37,062
-1,092 Reduced 0.71%
151,886 $4.37 Million
Q3 2023

Nov 01, 2023

SELL
$32.09 - $37.51 $29,554 - $34,546
-921 Reduced 0.6%
152,978 $5.07 Million
Q2 2023

Aug 08, 2023

SELL
$36.12 - $41.79 $1,805 - $2,089
-50 Reduced 0.03%
153,899 $5.65 Million
Q1 2023

May 04, 2023

SELL
$39.39 - $51.28 $23,634 - $30,768
-600 Reduced 0.39%
153,949 $6.28 Million
Q3 2022

Nov 09, 2022

SELL
$43.76 - $53.42 $192,368 - $234,834
-4,396 Reduced 2.77%
154,549 $6.76 Million
Q2 2022

Aug 02, 2022

SELL
$46.53 - $55.17 $63,839 - $75,693
-1,372 Reduced 0.86%
158,945 $8.33 Million
Q1 2022

May 09, 2022

BUY
$45.75 - $56.69 $155,550 - $192,746
3,400 Added 2.17%
160,317 $8.3 Million
Q4 2021

Feb 08, 2022

BUY
$41.32 - $61.25 $296,801 - $439,958
7,183 Added 4.8%
156,917 $9.27 Million
Q3 2021

Nov 09, 2021

SELL
$39.25 - $50.42 $11,343 - $14,571
-289 Reduced 0.19%
149,734 $6.44 Million
Q2 2021

Aug 05, 2021

SELL
$35.91 - $40.68 $73,076 - $82,783
-2,035 Reduced 1.34%
150,023 $5.88 Million
Q1 2021

Apr 28, 2021

SELL
$33.49 - $37.77 $13,630 - $15,372
-407 Reduced 0.27%
152,058 $5.51 Million
Q4 2020

Feb 08, 2021

SELL
$33.47 - $42.56 $80,930 - $102,910
-2,418 Reduced 1.56%
152,465 $5.61 Million
Q3 2020

Oct 26, 2020

BUY
$31.75 - $37.25 $295,084 - $346,201
9,294 Added 6.38%
154,883 $5.68 Million
Q2 2020

Aug 06, 2020

BUY
$30.12 - $36.54 $586,376 - $711,360
19,468 Added 15.44%
145,589 $4.76 Million
Q1 2020

Apr 30, 2020

SELL
$27.03 - $38.62 $75,305 - $107,595
-2,786 Reduced 2.16%
126,121 $4.12 Million
Q4 2019

Feb 03, 2020

BUY
$32.92 - $37.36 $84,341 - $95,716
2,562 Added 2.03%
128,907 $5.05 Million
Q3 2019

Nov 07, 2019

SELL
$32.49 - $42.13 $71,120 - $92,222
-2,189 Reduced 1.7%
126,345 $4.54 Million
Q2 2019

Jul 24, 2019

BUY
$36.98 - $41.52 $25,738 - $28,897
696 Added 0.54%
128,534 $5.57 Million
Q1 2019

May 13, 2019

BUY
$37.5 - $41.2 $694,087 - $762,570
18,509 Added 16.93%
127,838 $5.43 Million
Q4 2018

Jan 31, 2019

SELL
$38.47 - $43.86 $79,209 - $90,307
-2,059 Reduced 1.85%
109,329 $4.77 Million
Q3 2018

Nov 14, 2018

BUY
$34.47 - $41.81 $18,234 - $22,117
529 Added 0.48%
111,388 $4.91 Million
Q2 2018

Aug 06, 2018

SELL
$32.98 - $35.16 $33,606 - $35,828
-1,019 Reduced 0.91%
110,859 $4.02 Million
Q1 2018

May 07, 2018

SELL
$31.91 - $37.02 $50,130 - $58,158
-1,571 Reduced 1.38%
111,878 $3.97 Million
Q4 2017

Feb 06, 2018

BUY
$33.26 - $35.29 $16,995 - $18,033
511 Added 0.45%
113,449 $4.11 Million
Q3 2017

Nov 13, 2017

SELL
$31.0 - $34.15 $257,145 - $283,274
-8,295 Reduced 6.84%
112,938 $4.03 Million
Q2 2017

Aug 14, 2017

BUY
N/A
121,233
121,233 $4.07 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $159B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Hyman Charles D Portfolio

Follow Hyman Charles D and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hyman Charles D, based on Form 13F filings with the SEC.

News

Stay updated on Hyman Charles D with notifications on news.